Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Emilio Esteban González"'
Autor:
Paula González Villarroel, Josep Gumà Padró, Gloria Marquina, Noelia Martínez Jáñez, Emilio Esteban González, Antonio Antón, Miguel Berzosa Sánchez, Alberto Rodrigo Cáceres, Rafael López-López, Roberto Escala Cornejo, Pablo Borrega García, Raquel Marse Fabregat, Beatriz Castelo Fernández, Cristina López Bermudo, Carlos Camps
Publikováno v:
González Villarroel, Paula Gumà Padró, Josep Marquina, Gloria Martínez Jáñez, Noelia Esteban González, Emilio Antón, Antonio Berzosa Sánchez, Miguel Rodrigo Cáceres, Alberto López López, Rafael Escala Cornejo, Roberto Borrega García, Pablo Marse Fabregat, Raquel Castelo Fernández, Beatriz López Bermudo, Cristina Camps Herrero, Carlos 2022 Increased quality of life in patients with breakthrough cancer pain after individualized therapy : the CAVIDIOM study Future Oncology 18 35 3913 3927
Cancer patients can experience flares of pain, called breakthrough pain (BTcP), despite treatment with painkillers. Although BTcP can be excruciating, its intensity and other characteristics depend on several factors, including its treatment. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::649f6ff8416de9fdc212b930b89bee23
https://pubmed.ncbi.nlm.nih.gov/36537885
https://pubmed.ncbi.nlm.nih.gov/36537885
Autor:
Emilio Esteban González, Raúl Poza de Celis, Manuel Dómine Gómez, Susana Traseira Lugilde, Blanca Cantos Sánchez de Ibargüen, Jaume Capdevila Castillón, Ignacio Peláez Fernández, Rafael Trujillo Vílchez, Luis Zugazabeitia Olabarría, Joaquina Martínez Lozano, Nieves Fernandez
Publikováno v:
Advances in Therapy. 34:136-147
Bone metastasis is the most common cause of cancer-related pain, and metastatic bone pain (MBP) is not only severe but also progressive in many patients. The aim of this study was to investigate the association between pain management and performance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9549df31f72dcbd23b12b74f003d565c
https://doi.org/10.1007/s12325-016-0435-1
https://doi.org/10.1007/s12325-016-0435-1
Publikováno v:
Medicina clinica. 146
In the last 10 years, there has been a major change in the treatment of lung cancer (LC). The discovery of activating mutations in the epidermal growth factor receptor (EGFR) in some histological subtypes of LC and its sensitivity to tyrosine kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::04d5974530684009a73d7be81f1f58f4
https://pubmed.ncbi.nlm.nih.gov/27426241
https://pubmed.ncbi.nlm.nih.gov/27426241
Autor:
Emilio Esteban-González, Luis León, Martin Lázaro-Quintela, Sergio Vazquez-Estevez, Luis M. Antón-Aparicio
Publikováno v:
Renal Cell Carcinoma ISBN: 9781493916214
Treatment of metastatic renal cell carcinoma (mRCC) has evolved rapidly over the last years, from the era of immunological therapies to targeted agents. New drugs, vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0409d2d030b4e8b07a3b28a6c14042
https://doi.org/10.1007/978-1-4939-1622-1_18
https://doi.org/10.1007/978-1-4939-1622-1_18
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 37(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::890081252d09638c6b2d094d41303b2f
https://pubmed.ncbi.nlm.nih.gov/22030162
https://pubmed.ncbi.nlm.nih.gov/22030162